captopril ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
angiotensin-converting enzyme inhibitors 484 62571-86-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • captopril
  • (-)-Captopril
  • L-Captopril
  • lopirin
  • S-Captopril
  • SQ14225
  • SQ-14225
  • SQ 14225
A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.
  • Molecular weight: 217.28
  • Formula: C9H15NO3S
  • CLOGP: 0.89
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 57.61
  • ALOGS: -1.68
  • ROTB: 3

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 160 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 38 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 19.72 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 69 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.75 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 12 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.73 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
April 6, 1981 FDA PAR PHARM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxic epidermal necrolysis 78.14 14.13 51 10631 20941 50573501
Segmental diverticular colitis 72.39 14.13 14 10668 125 50594317
Pedal pulse abnormal 71.61 14.13 14 10668 133 50594309
Cardiac failure congestive 70.62 14.13 88 10594 84294 50510148
Blood pressure abnormal 65.37 14.13 38 10644 12709 50581733
Calcium ionised decreased 63.17 14.13 14 10668 255 50594187
Multiple organ dysfunction syndrome 58.11 14.13 62 10620 50275 50544167
Reduced facial expression 57.99 14.13 19 10663 1575 50592867
Feeding intolerance 54.02 14.13 14 10668 505 50593937
Dermatitis exfoliative 48.34 14.13 23 10659 5119 50589323
Insulin autoimmune syndrome 47.75 14.13 9 10673 69 50594373
Listless 46.86 14.13 18 10664 2372 50592070
Restlessness 44.11 14.13 39 10643 25134 50569308
Head discomfort 44.02 14.13 28 10654 10991 50583451
Labile hypertension 40.87 14.13 11 10671 460 50593982
Myocardial infarction 38.36 14.13 68 10614 88959 50505483
Left ventricular hypertrophy 37.56 14.13 19 10663 4826 50589616
Electrolyte imbalance 37.06 14.13 30 10652 17139 50577303
Hyperthyroidism 36.77 14.13 26 10656 12149 50582293
Cardiac failure 36.59 14.13 61 10621 75979 50518463
Prescription drug used without a prescription 34.03 14.13 13 10669 1687 50592755
Self-injurious ideation 33.98 14.13 14 10668 2215 50592227
Apathy 32.21 14.13 20 10662 7528 50586914
Cholecystitis 31.57 14.13 25 10657 13846 50580596
Haemodynamic instability 31.09 14.13 20 10662 8004 50586438
Foreign body 28.77 14.13 12 10670 1959 50592483
Immobile 28.40 14.13 16 10666 5038 50589404
Dehydration 27.94 14.13 83 10599 152366 50442076
Gastrointestinal sounds abnormal 27.43 14.13 14 10668 3620 50590822
Fatigue 27.38 14.13 69 10613 707532 49886910
Affect lability 26.67 14.13 19 10663 8979 50585463
Hyponatraemia 26.51 14.13 61 10621 96078 50498364
Occupational exposure to product 26.41 14.13 11 10671 1789 50592653
Hypertensive crisis 26.33 14.13 22 10660 13132 50581310
Cognitive disorder 26.21 14.13 39 10643 44084 50550358
Metabolic acidosis 25.51 14.13 36 10646 38789 50555653
Joint swelling 25.42 14.13 10 10672 245276 50349166
Drug interaction 25.32 14.13 96 10586 199525 50394917
Respiratory disorder 25.21 14.13 32 10650 31155 50563287
Acute myocardial infarction 25.21 14.13 31 10651 29242 50565200
Skin test positive 24.61 14.13 8 10674 647 50593795
Renal failure 24.43 14.13 63 10619 106570 50487872
Hypokalaemia 23.34 14.13 55 10627 87937 50506505
Cholelithiasis 23.18 14.13 34 10648 37939 50556503
Abdominal discomfort 23.10 14.13 10 10672 231631 50362811
Arthralgia 22.74 14.13 36 10646 438666 50155776
Cross sensitivity reaction 22.23 14.13 10 10672 1959 50592483
Acute kidney injury 22.11 14.13 101 10581 227957 50366485
Vascular stent thrombosis 22.04 14.13 8 10674 901 50593541
Blood urea increased 21.98 14.13 26 10656 23559 50570883
Atrial fibrillation 21.16 14.13 58 10624 101687 50492755
Hypotension 21.16 14.13 102 10580 235367 50359075
Renal injury 20.63 14.13 16 10666 8595 50585847
Systemic lupus erythematosus 19.84 14.13 3 10679 140619 50453823
Cyanosis 19.84 14.13 20 10662 15164 50579278
Rheumatoid arthritis 19.78 14.13 9 10673 202541 50391901
Hyperkalaemia 19.76 14.13 36 10646 48053 50546389
Pain 19.70 14.13 60 10622 578843 50015599
Progressive supranuclear palsy 19.61 14.13 4 10678 48 50594394
Alopecia 19.50 14.13 14 10668 245033 50349409
Contraindicated product administered 19.23 14.13 4 10678 148954 50445488
Infusion related reaction 19.12 14.13 6 10676 169551 50424891
Cardiac failure acute 19.05 14.13 15 10667 8235 50586207
Therapeutic product effect decreased 18.97 14.13 3 10679 136047 50458395
Circulatory collapse 18.55 14.13 22 10660 19978 50574464
Posterior reversible encephalopathy syndrome 18.30 14.13 19 10663 14909 50579533
Elastosis perforans 17.99 14.13 3 10679 10 50594432
Artery dissection 17.99 14.13 4 10678 74 50594368
Nodal rhythm 17.72 14.13 8 10674 1579 50592863
Coronary artery disease 17.25 14.13 26 10656 29700 50564742
Stevens-Johnson syndrome 17.08 14.13 22 10660 21730 50572712
Scleroderma renal crisis 17.04 14.13 5 10677 287 50594155
Cerebrovascular accident 16.81 14.13 51 10631 94629 50499813
Bradycardia 16.79 14.13 40 10642 64386 50530056
Urinary retention 16.78 14.13 24 10658 26166 50568276
Extrasystoles 16.56 14.13 11 10671 4644 50589798
Shock 16.39 14.13 21 10661 20629 50573813
Potentiating drug interaction 16.00 14.13 10 10672 3806 50590636
Drug ineffective 15.77 14.13 105 10577 819228 49775214
Renal impairment 15.59 14.13 43 10639 75618 50518824
Off label use 15.53 14.13 50 10632 474376 50120066
Blood creatinine increased 15.42 14.13 43 10639 76117 50518325
Bedridden 15.39 14.13 14 10668 9353 50585089
Encephalopathy 14.82 14.13 26 10656 33685 50560757
Occupational dermatitis 14.70 14.13 3 10679 36 50594406
Maternal exposure during pregnancy 14.25 14.13 8 10674 159770 50434672

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood ketone body increased 35.93 14.68 10 7915 372 29566230
Cyanosis 33.03 14.68 26 7899 11241 29555361
Scleroderma renal crisis 31.32 14.68 7 7918 103 29566499
Angioedema 28.79 14.68 39 7886 31876 29534726
Cardiac failure congestive 26.08 14.68 61 7864 76520 29490082
Hypertensive crisis 24.94 14.68 19 7906 7829 29558773
Renal failure 23.95 14.68 78 7847 118521 29448081
Kidney small 23.80 14.68 5 7920 54 29566548
Myocardial infarction 22.68 14.68 73 7852 110223 29456379
Long QT syndrome 21.52 14.68 11 7914 2247 29564355
Cerebrovascular accident 19.67 14.68 55 7870 76856 29489746
Coronary artery disease 19.37 14.68 39 7886 44151 29522451
Indifference 19.36 14.68 5 7920 139 29566463
Blood creatinine increased 19.03 14.68 58 7867 85044 29481558
Pulmonary hypertensive crisis 18.66 14.68 5 7920 161 29566441
Hypokalaemia 18.19 14.68 41 7884 50162 29516440
Vitamin B12 deficiency 17.71 14.68 11 7914 3260 29563342
Reaction to excipient 17.65 14.68 6 7919 438 29566164
Renal failure neonatal 16.74 14.68 4 7921 80 29566522
Vascular resistance systemic decreased 15.90 14.68 4 7921 100 29566502
Bronchospasm 15.82 14.68 16 7909 9593 29557009
Arrhythmia 15.38 14.68 29 7896 31284 29535318
Drug reaction with eosinophilia and systemic symptoms 15.11 14.68 27 7898 27965 29538637
Renal impairment 15.07 14.68 52 7873 81281 29485321
Haemorrhagic necrotic pancreatitis 15.04 14.68 4 7921 125 29566477
Cardiac failure 14.96 14.68 51 7874 79236 29487366

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cardiac failure congestive 82.05 12.63 131 16311 130449 64351841
Segmental diverticular colitis 69.75 12.63 14 16428 125 64482165
Pedal pulse abnormal 67.87 12.63 14 16428 145 64482145
Myocardial infarction 56.31 12.63 128 16314 165693 64316597
Toxic epidermal necrolysis 53.04 12.63 56 16386 37110 64445180
Calcium ionised decreased 50.90 12.63 14 16428 524 64481766
Feeding intolerance 50.05 12.63 14 16428 558 64481732
Cyanosis 45.96 12.63 41 16401 22114 64460176
Hypertensive crisis 42.35 12.63 36 16406 18212 64464078
Reduced facial expression 42.23 12.63 17 16425 2096 64480194
Cardiac failure 40.35 12.63 98 16344 132275 64350015
Renal failure 39.77 12.63 119 16323 181569 64300721
Multiple organ dysfunction syndrome 38.60 12.63 82 16360 101331 64380959
Labile hypertension 37.45 12.63 11 16431 523 64481767
Scleroderma renal crisis 35.91 12.63 10 16432 392 64481898
Occupational exposure to product 35.87 12.63 11 16431 607 64481683
Completed suicide 35.58 12.63 7 16435 224407 64257883
Blood pressure abnormal 34.57 12.63 29 16413 14406 64467884
Electrolyte imbalance 34.18 12.63 37 16405 25206 64457084
Cerebrovascular accident 33.85 12.63 94 16348 137489 64344801
Head discomfort 33.04 12.63 26 16416 11808 64470482
Coronary artery disease 33.03 12.63 57 16385 60376 64421914
Insulin autoimmune syndrome 32.39 12.63 9 16433 350 64481940
Angioedema 32.09 12.63 57 16385 61764 64420526
Apathy 32.05 12.63 25 16417 11207 64471083
Listless 32.02 12.63 16 16426 3274 64479016
Dermatitis exfoliative 31.64 12.63 24 16418 10328 64471962
Blood creatinine increased 29.76 12.63 89 16353 135693 64346597
Self-injurious ideation 29.51 12.63 15 16427 3182 64479108
Joint swelling 27.94 12.63 10 16432 215372 64266918
Blood ketone body increased 27.37 12.63 9 16433 623 64481667
Hypotension 26.55 12.63 177 16265 380797 64101493
Restlessness 26.44 12.63 41 16401 39744 64442546
Prescription drug used without a prescription 26.36 12.63 13 16429 2587 64479703
Gastrointestinal sounds abnormal 26.23 12.63 16 16426 4827 64477463
Hyperthyroidism 25.23 12.63 27 16415 18152 64464138
Drug interaction 25.09 12.63 168 16274 361915 64120375
Acute myocardial infarction 24.95 12.63 55 16387 69663 64412627
Pulmonary hypoplasia 24.05 12.63 5 16437 54 64482236
Hypokalaemia 24.01 12.63 77 16365 121826 64360464
Renal impairment 23.67 12.63 82 16360 134935 64347355
Cholecystitis 23.52 12.63 27 16415 19609 64462681
Hyponatraemia 23.38 12.63 87 16355 148252 64334038
Cross sensitivity reaction 23.19 12.63 13 16429 3354 64478936
Rheumatoid arthritis 22.40 12.63 7 16435 164287 64318003
Cholelithiasis 22.39 12.63 41 16401 45465 64436825
Respiratory disorder 22.32 12.63 36 16406 36075 64446215
Off label use 22.03 12.63 85 16357 632721 63849569
Bradycardia 21.78 12.63 73 16369 118146 64364144
Foreign body 21.06 12.63 11 16431 2468 64479822
Indifference 20.90 12.63 6 16436 263 64482027
Immobile 20.75 12.63 15 16427 6000 64476290
Posterior reversible encephalopathy syndrome 20.16 12.63 27 16415 22919 64459371
Fatigue 19.90 12.63 111 16331 748619 63733671
Renal injury 19.82 12.63 22 16420 15407 64466883
Skin test positive 19.43 12.63 8 16434 1045 64481245
Affect lability 19.37 12.63 17 16425 8973 64473317
Cognitive disorder 19.19 12.63 43 16399 55044 64427246
Arthralgia 19.10 12.63 54 16388 442206 64040084
Left ventricular hypertrophy 18.55 12.63 17 16425 9489 64472801
Drug reaction with eosinophilia and systemic symptoms 18.53 12.63 42 16400 54175 64428115
Hypertension 18.36 12.63 121 16321 259140 64223150
Long QT syndrome 18.15 12.63 13 16429 5126 64477164
COVID-19 treatment 17.90 12.63 6 16436 441 64481849
Pulmonary oedema 17.63 12.63 52 16390 78622 64403668
Ventricular extrasystoles 17.55 12.63 22 16420 17507 64464783
Elastosis perforans 17.21 12.63 3 16439 11 64482279
Blood urea increased 17.13 12.63 36 16406 44117 64438173
Haemorrhagic necrotic pancreatitis 17.09 12.63 4 16438 77 64482213
Nasopharyngitis 16.97 12.63 15 16427 196058 64286232
Abdominal discomfort 16.95 12.63 13 16429 182309 64299981
Congenital anomaly 16.74 12.63 5 16437 252 64482038
Kidney small 16.65 12.63 5 16437 257 64482033
Dehydration 16.47 12.63 103 16339 216660 64265630
Tongue oedema 16.37 12.63 13 16429 5977 64476313
Blood potassium increased 16.19 12.63 26 16416 25954 64456336
Drug ineffective 16.15 12.63 137 16305 840110 63642180
Oligohydramnios 16.10 12.63 10 16432 3114 64479176
Atrial fibrillation 16.06 12.63 86 16356 171003 64311287
Arrhythmia 15.90 12.63 39 16403 52905 64429385
Progressive supranuclear palsy 15.83 12.63 4 16438 107 64482183
Hyperplasia 15.78 12.63 7 16435 1097 64481193
Pulmonary hypertensive crisis 15.65 12.63 5 16437 316 64481974
Cardiac failure acute 15.55 12.63 20 16422 16324 64465966
Klebsiella infection 15.47 12.63 18 16424 13263 64469027
Haemodynamic instability 15.38 12.63 19 16423 14893 64467397
Extrasystoles 15.17 12.63 13 16429 6645 64475645
Infusion related reaction 14.94 12.63 12 16430 164455 64317835
Lower respiratory tract infection 14.88 12.63 3 16439 94611 64387679
Hyperkalaemia 14.84 12.63 58 16384 101071 64381219
Nodal rhythm 14.31 12.63 9 16433 2865 64479425
Lactic acidosis 14.15 12.63 41 16401 61369 64420921
Bedridden 14.00 12.63 15 16427 10094 64472196
Scleroedema 13.99 12.63 3 16439 38 64482252
Alopecia 13.95 12.63 13 16429 165677 64316613
Shock 13.48 12.63 30 16412 38210 64444080
Artery dissection 13.31 12.63 4 16438 206 64482084
Rhythm idioventricular 13.26 12.63 5 16437 518 64481772
Pulmonary hypertension 13.19 12.63 32 16410 43107 64439183
Vitamin B12 deficiency 13.11 12.63 11 16431 5461 64476829
Vascular resistance systemic decreased 13.09 12.63 4 16438 218 64482072
Injection site pain 13.09 12.63 6 16436 111402 64370888
Acute interstitial pneumonitis 12.94 12.63 6 16436 1041 64481249
Apraxia 12.89 12.63 8 16434 2487 64479803
Stomatitis 12.73 12.63 6 16436 109599 64372691

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C09AA01 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, PLAIN
ACE inhibitors, plain
ATC C09BA01 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors and diuretics
FDA MoA N0000000181 Angiotensin-converting Enzyme Inhibitors
FDA EPC N0000175562 Angiotensin Converting Enzyme Inhibitor
CHEBI has role CHEBI:35457 ACE inhibitor
CHEBI has role CHEBI:35674 antihypertensive drugs
MeSH PA D000806 Angiotensin-Converting Enzyme Inhibitors
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011480 Protease Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Chronic heart failure indication 48447003
Diabetic renal disease indication 127013003
Left ventricular cardiac dysfunction indication 429589006
Atrial fibrillation off-label use 49436004 DOID:0060224
Cystinuria off-label use 85020001 DOID:9266
Diastolic heart failure off-label use 418304008 DOID:9775
Cystine Renal Calculi off-label use
Nondiabetic Proteinuric Nephropathy off-label use
Anuria contraindication 2472002 DOID:2983
Hypercholesterolemia contraindication 13644009
Hyperkalemia contraindication 14140009
Secondary angle-closure glaucoma contraindication 21571006
Hypovolemia contraindication 28560003
Acute cerebrovascular insufficiency contraindication 29322000
Dehydration contraindication 34095006
Hyperuricemia contraindication 35885006 DOID:1920
Immunosuppression contraindication 38013005
Angioedema contraindication 41291007 DOID:1558
Hypokalemia contraindication 43339004
Low blood pressure contraindication 45007003
Cough contraindication 49727002
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Aortic valve stenosis contraindication 60573004 DOID:1712
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Hypochloremic alkalosis contraindication 70134007
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Transplantation contraindication 77465005
Hereditary angioneurotic edema contraindication 82966003 DOID:14735
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Disorder of connective tissue contraindication 105969002 DOID:65
Hypomagnesemia contraindication 190855004
Acute pancreatitis contraindication 197456007 DOID:2913
Hypertrophic cardiomyopathy contraindication 233873004 DOID:11984
Disease of liver contraindication 235856003 DOID:409
Neonatal hyperbilirubinemia contraindication 281610001
Pregnancy, function contraindication 289908002
Renal artery stenosis contraindication 302233006
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
Azotemia contraindication 445009001
Hemodialysis with High-Flux Membrane contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.85 acidic
pKa2 9.56 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Angiotensin-converting enzyme Enzyme INHIBITOR Ki 8.70 WOMBAT-PK CHEMBL
Prostaglandin G/H synthase 2 Enzyme Ki 4.92 CHEMBL
Prostaglandin G/H synthase 1 Enzyme Ki 4.77 CHEMBL
Prothrombin Enzyme Ki 7.32 CHEMBL
Renin Enzyme Ki 8.77 CHEMBL
Leukotriene A-4 hydrolase Enzyme IC50 7.15 CHEMBL
Angiotensin-converting enzyme Enzyme Ki 8.77 CHEMBL
Angiotensin-converting enzyme Enzyme Ki 8.70 CHEMBL
Succinyl-diaminopimelate desuccinylase Enzyme Ki 5.74 CHEMBL
Beta-lactamase Enzyme Ki 5.62 CHEMBL
Beta-lactamase II Enzyme Ki 4.75 CHEMBL
Beta-lactamase class B VIM-2 Unclassified Kd 6.22 CHEMBL
Beta-lactamase NDM-1 Enzyme Kd 4.85 CHEMBL

External reference:

IDSource
4017614 VUID
N0000145994 NUI
D00251 KEGG_DRUG
1998 RXNORM
C0006938 UMLSCUI
CHEBI:3380 CHEBI
X8Z PDB_CHEM_ID
CHEMBL1560 ChEMBL_ID
DB01197 DRUGBANK_ID
D002216 MESH_DESCRIPTOR_UI
44093 PUBCHEM_CID
4373 INN_ID
5158 IUPHAR_LIGAND_ID
9G64RSX1XD UNII
4347 MMSL
455 MMSL
d00006 MMSL
000656 NDDF
29439004 SNOMEDCT_US
387160004 SNOMEDCT_US
4017614 VANDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 0143-1171 TABLET 12.50 mg ORAL ANDA 22 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 0143-1172 TABLET 25 mg ORAL ANDA 22 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 0143-1173 TABLET 50 mg ORAL ANDA 22 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 0143-1174 TABLET 100 mg ORAL ANDA 22 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 0615-4519 TABLET 12.50 mg ORAL ANDA 21 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 0615-4520 TABLET 25 mg ORAL ANDA 21 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 0615-4521 TABLET 50 mg ORAL ANDA 21 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 0781-8052 TABLET 12.50 mg ORAL ANDA 16 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 0781-8061 TABLET 25 mg ORAL ANDA 16 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 0781-8075 TABLET 50 mg ORAL ANDA 16 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 0781-8080 TABLET 100 mg ORAL ANDA 16 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 0904-5045 TABLET 12.50 mg ORAL ANDA 22 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 0904-5046 TABLET 25 mg ORAL ANDA 22 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 0904-5047 TABLET 50 mg ORAL ANDA 22 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 0904-7105 TABLET 12.50 mg ORAL ANDA 12 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 0904-7106 TABLET 25 mg ORAL ANDA 12 sections
CAPTOPRIL HUMAN PRESCRIPTION DRUG LABEL 1 10544-175 TABLET 50 mg ORAL ANDA 19 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 21695-477 TABLET 25 mg ORAL ANDA 24 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 21695-478 TABLET 50 mg ORAL ANDA 24 sections
Captopril Human Prescription Drug Label 1 27241-160 TABLET 12.50 mg ORAL ANDA 12 sections
Captopril Human Prescription Drug Label 1 27241-161 TABLET 25 mg ORAL ANDA 12 sections
Captopril Human Prescription Drug Label 1 27241-162 TABLET 50 mg ORAL ANDA 12 sections
Captopril Human Prescription Drug Label 1 27241-163 TABLET 100 mg ORAL ANDA 12 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 31722-141 TABLET 12.50 mg ORAL ANDA 24 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 31722-142 TABLET 25 mg ORAL ANDA 24 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 31722-143 TABLET 50 mg ORAL ANDA 24 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 31722-144 TABLET 100 mg ORAL ANDA 24 sections
CAPTOPRIL HUMAN PRESCRIPTION DRUG LABEL 1 33261-182 TABLET 50 mg ORAL ANDA 19 sections
CAPTOPRIL HUMAN PRESCRIPTION DRUG LABEL 1 33261-536 TABLET 100 mg ORAL ANDA 19 sections
CAPTOPRIL HUMAN PRESCRIPTION DRUG LABEL 1 33261-974 TABLET 25 mg ORAL ANDA 19 sections